US20110111973A1 - Broad specificity affinity arrays: a qualitative approach to complex sample discrimination - Google Patents

Broad specificity affinity arrays: a qualitative approach to complex sample discrimination Download PDF

Info

Publication number
US20110111973A1
US20110111973A1 US12/911,125 US91112510A US2011111973A1 US 20110111973 A1 US20110111973 A1 US 20110111973A1 US 91112510 A US91112510 A US 91112510A US 2011111973 A1 US2011111973 A1 US 2011111973A1
Authority
US
United States
Prior art keywords
sample
lectins
mass increase
biological
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/911,125
Inventor
Michael Mecklenburg
Bengt Danielsson
Fredrick Winqvist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/911,125 priority Critical patent/US20110111973A1/en
Publication of US20110111973A1 publication Critical patent/US20110111973A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54373Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277Apparatus
    • B01J2219/00497Features relating to the solid phase supports
    • B01J2219/00527Sheets
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00585Parallel processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00596Solid-phase processes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/0061The surface being organic
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00612Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00623Immobilisation or binding
    • B01J2219/0063Other, e.g. van der Waals forces, hydrogen bonding
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00605Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00632Introduction of reactive groups to the surface
    • B01J2219/00637Introduction of reactive groups to the surface by coating it with another layer
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583Features relative to the processes being carried out
    • B01J2219/00603Making arrays on substantially continuous surfaces
    • B01J2219/00659Two-dimensional arrays
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/0068Means for controlling the apparatus of the process
    • B01J2219/00702Processes involving means for analysing and characterising the products
    • B01J2219/00707Processes involving means for analysing and characterising the products separated from the reactor apparatus
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718Type of compounds synthesised
    • B01J2219/0072Organic compounds
    • B01J2219/00722Nucleotides
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718Type of compounds synthesised
    • B01J2219/0072Organic compounds
    • B01J2219/00725Peptides
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718Type of compounds synthesised
    • B01J2219/0072Organic compounds
    • B01J2219/00729Peptide nucleic acids [PNA]
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/06Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/10Libraries containing peptides or polypeptides, or derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20Immunohistochemistry assay
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/808Optical sensing apparatus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/969Multiple layering of reactants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/973Simultaneous determination of more than one analyte
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/807Apparatus included in process claim, e.g. physical support structures
    • Y10S436/809Multifield plates or multicontainer arrays

Definitions

  • the invention takes advantage of the ability of neural, network and statistical software to analyse complex patterns generated using arrays of discrete sensing elements with intermediate affinities and specificities (broad specificity) as a strategy for complex sample discrimination.
  • Discrete sensing elements with appropriate affinities and specificities are chosen such that each element in the array has an acceptable signal to noise ratio.
  • the informational content obtained from this assay strategy would be meaningless if analysed using conventional methods, i.e. positive vs negative type analysis.
  • a pattern recognition based data analysis procedure is employed using, but not limited to, neural network and statistical software must be developed and/or adapted must be employed in order to be able to discriminate complex samples. Pattern recognition forms the basis for the discrimination process that takes full advantage of the increased informational content of this diagnostic strategy.
  • the bound material is quantitated by determining the increase in thickness or mass on the surface of the sensor.
  • This can be accomplished using a number of nonlabel detection principles including, but not limited to, quartz crystal microbalances, optical techniques such as optoaucostics, reflectometry, ellipsometry and surface plasmon resonance (SPR).
  • An essential aspect of the strategy is the fact that the constituents bound to the sensing elements need not be identified to perform the assay. This makes it possible to use recognition elements with complex interactions such as those found in nature.
  • the samples are discriminated by correlating the values from the entire array using pattern recognition and compared to a reference sample. This increases the speed and reduces the time required to perform assays, thereby reducing costs all of which are objects of this invention.
  • arrays of lectins are used in combination with neural network analysis as a diagnostic tool to discriminate complex samples, such as serum samples.
  • Lectins are immobilized onto discrete areas in an array onto planar gold coated surfaces using empirically developed high density immobilization protocols.
  • This embodiment of the invention takes advantage of the ability of lectins to recognize saccharides, oligosaccharides and other as yet unknown ligands both natural and synthetic which have an affinity for lectins, free or attached to proteins (glycoproteins), lipids (glycolipids) and other biomolecules.
  • the ubiquitous presence of carbohydrates in all living organisms provides a nearly universal means for identification of complex biological samples.
  • the complex biosynthetic pathways used to synthesize these carbohydrates are effected by subtle changes in their environment. These changes lead to a series of complex global modifications in the composition and thereby the structure of the carbohydrates.
  • This invention takes advantage of this diversity in order to increase the amount of information that can be obtained, instead of quantitating the exact amount of a particular compound that has bound to a specific lectin as is routinely done in conventional diagnostics.
  • the use of arrays of lectins enables the identification of global changes in complex samples, thereby allowing discrimination.
  • An additional object of the invention is the ability of the assay strategy to take advantage of as yet unidentified recognition capabilities present on biomolecules. These unidentified recognition elements will provide information that allow the discrimination of samples with unprecedented accuracy and presently not possible with any other diagnostic assay strategy.
  • An application of this invention involves the use of lectin arrays to discriminate sera from different animal species.
  • the constituent(s) bound to each lectin in the array is quantitated using a fixed angle ellipsometer.
  • the responses obtained from these experiments were used to train the artificial neural network.
  • the resulting trained network was able to discriminate all of the serum samples.
  • the assay shows the utility of the invention for the general identification of complex biological material.
  • Another application of the lectin affinity array was for the discrimination of “healthy” and “sick” individuals (humans).
  • Chemical sensor arrays can be used to identify and classify complex gas mixtures or odors (Shurmer, H. V., An electronic nose: A sensitive and discriminating substitute for a mammalian olfactory system, IEEE proc. G 137, 197-204, 1990; Gardner, J. W. and Bartlett, P. N. (eds), Sensors and Sensory Systems for an Electronic Nose, Proc. NATO Advances Research Workshop, Reykjavik, 1992.). Chemical sensors are in general non-specific, but have different selectivity patterns towards the species in the odor.
  • the basis for the human olfactory sense is that a signal pattern is generated from the receptors cells in the olfactory bulb.
  • the receptor cells are not specific for a particular molecules, but rather belong to different selectivity classes.
  • the basis for olfaction (smell) appears to combine the signals obtained from each of the low specificity receptor classes.
  • the combinatorial effect that results leads to an increase in the discriminatory ability of the system (despite the relatively small number of receptor classes).
  • the chemical sensing elements can recognize odors but lack the discrete recognition capabilities that biomolecules and synthetic biomimetic molecules possess.
  • One object of the invention is to apply discrete biosensing elements in a fashion that increases the informational content of the diagnostic assay. This would require the employment of a biomolecule with broad recognition characteristics which would normally be considered too ill-defined to be useful in conventional diagnostics.
  • the specificity must be chosen so as to obtain adequately broad binding (high informational content) but not so much as to make differentiation between specific and nonspecific binding impossible, i.e. adequate signal to noise ratio.
  • biological sensing elements must have well defined binding characteristics that are appropriate for this assay strategy.
  • the invention described here involves the development of a new assay strategy for complex sample discrimination using arrays of biorecognition elements that is far more informationally rich than conventional assays. Another object of this invention is to reduce the number of tests that must be performed before a diagnosis can be made, thereby reducing the time required to start treatment as well as the cost. Unlike standard diagnostic tests which detect known compounds highly specifically, we detect the binding of unknown compounds to the lectins.
  • the new assay strategy requires the employment of specialized nonlabel-based detection techniques, including but not limited to quartz crystal microbalances and optical techniques such as optoaucostics, reflectometry, ellipsometry and surface plasmon resonance (SPR). All of the methods that are based on polarized light reflected off a solid surface have already proven valuable for thickness determination of proteins on solid surfaces. The sensitivity of the methods are about the same, which is on the order of a few ⁇ ngströms.
  • Bio sensing elements Proteins have the ability to combine specifically and reversibly with a variety of ligands. Enzymes for example bind substrates and inhibitors while antibodies can be produced which bind a variety of antigens such as carbohydrates, proteins, and small molecules. Another class of proteins, lectins, have the ability to bind sugars and are devoid of enzymatic activity. Receptors bind a wide range of ligands with high affinity and specificity. Nature evolves and maintains proteins for specific purposes with adequate affinity and specificity for a particular purpose. Thus, the employment of biological or synthetic biomimetic sensing elements is the most appropriate approach for identifying changes that are of biological significance. We have chosen to test the biosensing affinity arrays invention described here using the lectins. We shall describe lectins and give several advantages this class of proteins has over the more commonly used immune-based diagnostics in the application of this invention.
  • Lectins as biological recognition elements. As mentioned previously, lectins bind carbohydrates and to compounds with similar structure. (Lectins as molecules and as tools. Lis, H. And Sharon, N. Ann. Rev. Biochem., 55, 35-67, 1986; Advances in Lectin Research . Vol 1, Franz, H. Ed., Springer-Verlag, Berlin, 187 pp., 1987). Lectins also have the capability to agglutinate cells, precipitating polysaccharides and glycoproteins and are of nonimmune origin. This is due to the fact that they are oligomeric in structure, usually containing one sugar binding site per subunit. In this respect, lectins have agglutinating abilities similar to those of antibodies. They also can be inhibited by low molecular weight compounds, which in the case of lectins are small carbohydrates, such as monosaccharide, oligosaccharides or macromolecules which contain them.
  • lectins provide a broad spectrum of well defined binding specificities with a high degree of cross reactivities as compared for example with antibodies and enzymes. Furthermore, they are stable and have a wide range of affinities and specificities. In addition, over one hundred lectins have been characterized. It now appears that lectins mediate a variety of cellular interactions during development and in the adult animal (Drickamer, K. And Taylor, M. E. Biology of Animal Lectins Annu. Rev. Cell Biol. 9:237-64, 1993). This is supported by data which shows that lectin expression patterns change throughout development and in response to a wide range of environmental changes [Varki, A.
  • oligosaccharides are Biological roles of oligosaccharides: all of the theories are correct, Glycobiology, 3:97-130, 1993.].
  • the involvement of oligosaccharides in selectin-mediated cell-cell recognition by the immune system in response to inflammation [Lasky, L. A. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science 258:964-969, 1992 and sperm-cell recognition during fertilization [Miller, D. J., Macek, M. B., Shur, B. D. Complementarity between sperm surface b1,4-galactosyltransferase and egg coat ZP3 mediates sperm-egg binding. Nature 357:589-593, 1992) are but a few examples.
  • glycosides and glycosyltransferases interferes with normal development.
  • An object of this invention is the ability of the assay strategy to discriminate complex samples which could be used to delineate complex basic developmental processes.
  • glycobiology Glycoproteins , Hughes, R. C. outline Studies in Biology, Chapman and Hall, London and New York, 95 pp, 1983.
  • Glycosylation is used extensively in nature for a wide range of purposes some general, such as protease protection, some directed to particular classes of proteins, such as signaling mechanism for clearance of proteins from serum and some highly specific, such as cell adhesion.
  • Carbohydrates also act as control mechanisms, as signals for cellular localization, for specific cell surface recognition of one cell type by another, for clearance of a particular glycoform from serum, assist in protein folding possibly by providing protection against proteolysis (Pareth, R. B. Effects of glycosylation on protein function. CUM Opin. Struct. Biol. 1:750-54, 1991).
  • Carbohydrates contain a potential informational content several orders of magnitude greater than any other biological oligomer. For example, if one calculates the number of possible structures for a hexamer of sugars and that of a hexamer of amino acids, the figure is >1.05 ⁇ 10 12 and 4.6 ⁇ 10 1 . The difference is more than seven orders of magnitude. Accordingly, sugars clearly provide the largest single source of diversity in the biological world (Laine, R. A. Invited Commentary in Glyco-Forum section Glycobiology 1994 8, 759-767).
  • Lectins have also been shown to be important in defense against a variety of pathogens.
  • the mannose binding lectins in animals mediates antibody-independent binding of pathogens which contain a high concentration of mannose on their surface.
  • These monosaccharides are not generally found in terminal positions on serum or cell surface glycoproteins in mammalian systems.
  • the recognition event can initiate the complement cascade [Ikeda, K, Sannoh, T., Kawasaki, T. And Yamashima, I. (1987) J. Biol. Chem. 262, 7451-7454.].
  • Plant lectins have also been implicated in attachment of symbiotic nitrogen fixing bacteria to the roots of leguminous plants and int eh protection of plants against fungal pathogens (Bohlool, B. B. and Schmidt, E. L. (1974) Science 185:269-71).
  • Viruses such as influenza virus (myxovirus) and Sendia virus (paramyxovirus) use a haemagglutonin protein that binds sialic acid containing receptors on the surface of target cells to initiate the virus-cell interaction (Paulsson, J. C. Interaction of animal viruses with cell surface receptors. in: The Receptors (Vol. 2) (ed. P.M. Conn), Academic Press, New York, pp. 131-219, 1985).
  • Another object of the invention is to study the pathogenesis of diseases that use carbohydrates or lectins in order to gain entry into cells.
  • Carbohydrate binding proteins such as selectins are believed to play a critical role in immune responses including inflammation (Springer, et al. 1991 Nature 349:196-197; Philips, et al., 1990 Science 250:1130-32.
  • Specific carbohydrate ligands have been identified and have been used to control inflammation, immunosuppression, etc. through their interaction with selectin proteins and/or other lectins (Gaeta, et al., U.S. patent application Ser. No. 07/538,853, filed 15 Jun. 1990; Ippolito, et al., U.S. patent application Ser. No. 07/889,017, filed 26 May 1992).
  • Other glycoproteins have also been shown to be useful in suppressing mammalian immune responses (Smith et al., U.S. patent application Ser. No. 07/956,043 filed 2 Oct. 1992).
  • Another object of the invention is to use the assay strategy in order to delineating the more subtle recognition functions of lectins, including but not limited to selectin and other lectins, in immune and inflammatory responses.
  • Lectins have been widely used to separate cells such as thymocytes and splenocytes (Reisner, Y, Sharon, N. 1984 Methods Enzymol. 108:168-79; Maekawa, M., Nishimune, Y. 1985 Biol. Reprod. 32:419-25.). Numerous bacteria have been typed using lectins (Doyle, R. J., Keller, K. F. 1984 Can. J. Microbiol. 3:4-9; DeLucca, A . J. II 1984 Can. J. Microbiol. 3:1100-4).
  • each individual enzymatic reaction may or may not go to completion, giving rise to glycoforms or glycosylated variants of the protein (Rademacher, et al. Ann. Rev. Biocehm., 1988 57:789-838).
  • These factors give rise to the enormous heterogeneity of carbohydrate structures, found in vivo that has hindered their analysis.
  • the relative concentration of the different forms have been shown to vary in specific ways in certain health and disease states. For example This also explains why glycosylation patterns of natural glycoproteins may be influenced by physiological changes such as pregnancy and also diseases such as rheumatoid arthritis.
  • an object of the invention would be the application of density gradients of lectins on surfaces in continuos and discontinuous, as well as in homogeneous and heterogeneous formats for sample discrimination. This would provide a unique tool for gaining a basic understanding of the effect of binding site density on the recognition process. Methods are available to those skilled in the art for adapting reflectometry, ellipsometry or SPR for scanning and imaging modes. This also would provide an additional assay parameter, thus increasing the informational content of the lectin affinity arrays and thereby improving their ability to discriminate complex samples.
  • Immunoassay based diagnostics currently predominate the market, nevertheless, lectins provide some advantages over conventional immunoassays. Lectins are present in most life forms and more importantly they are found in life forms such as plants, microorganisms and viruses, which do not synthesize immunoglobulin. Clearly the biological function(s) of lectins precedes that of the immune system, many of which are unknown at present. Thus, these sensing elements will be more useful for identification and classification purposes. The extensive homologies observed between different classes of lectins demonstrate that these proteins have been conserved throughout evolution and provide strong evidence that they have important function(s) in biology. Another difference is that lectins are structurally diverse whereas antibodies are structurally similar.
  • lectins combine the multivalency of antibodies with the structural diversity of enzymes.
  • Other proteins which bind carbohydrates also exist such as those that participate in carbohydrate metabolism and sugar transport. In general, these proteins only bind one carbohydrate and serve quite different purposes than lectins.
  • immunoassays are based upon the immunological reaction between proteins such as antibodies, antibody fragments, or even artificially generated elements simulating antibody binding sites such as peptides, templated polymers and the like (hereafter referred to as antibody recognition) and the substance for which they are specific, the ligand.
  • Immunological reactions are characterized by their high specificity and accordingly, numerous schemes have been developed in order to take advantage of this characteristic. The goal is to identify a particular state with absolute specificity using as few assays as possible.
  • an antibody is immobilized on a solid phase such as microparticles, microtiter wells, paddles, and the like.
  • the sample is then contacted with the immobilized antibody and the ligand binds if present in the sample.
  • the bound substance is detected and quantitated by an entity associated directly or indirectly therewith.
  • detectable entity include fluorescent molecules, chemiluminescent molecules, enzyme, isotopes, microparticles and the like.
  • Many variants have been developed such as competition, indirect competition, and the like.
  • Various methods are available to those skilled in the art for quantitating the amount of substance bound using these assays.
  • the assay strategy is capable of discriminating subtle changes and thus allows early identification of changes in the state of health that can be of crucial importance.
  • the sensing elements used in conventional assays will be applicable.
  • the specificity of these reagents will be too high to allow their use. Accordingly, new screening procedures will be developed in order to isolated reagents with appropriate combination of affinities and specificities and is an object of this invention, as well.
  • the assay strategy can be extended to a wide range of applications that require complex sample discrimination including but not limited to identification of diseases, identification of changes caused by the disease itself in the host (including but not limited to human, animal, plants and microorganisms).
  • Complex samples containing biological material and/or degradation products including but not limited to such as food stuffs like beverages, dry foods, and the like (including but not limited to quality control, for detection of unwanted microbial growth, freshness, physical damage), as well as the control of environmental samples for microbial flora (including but not limited to microbial content and composition), pollutants and their breakdown products in air, soil and water samples.
  • This strategy and assays based on it could also be used for monitoring fermentation processes, including but not limited to yogurt, beer, wine and the like, broths, as well as in fermentation processes in which products are produced such as biological compounds produced by microbial processes, such as insulin from genetically engineered bacteria and the like, as well as condiments made for seasoning and the like, as well fermentation processes used in the production of animal food stuffs.
  • Another object of the invention is to provide a strategy and assays for improved techniques to monitor the general state of health to assist efforts in identifying ailments early on thereby allowing treatment to begin at an earlier stage than would have been possible otherwise.
  • the early treatment of disease has been shown to reduce health care costs.
  • This strategy would also be useful in preventative health care schemes.
  • This diagnostic strategy based on the use of discrete recognition elements with broad recognition specificities combined with computer based artificial neural network data analysis can also be used with discrete synthetic biomimetic recognition elements with appropriate specificity (signal to noise). These could be made from modified biological material or from polymeric materials by conventional templating techniques and the like. This embodiment of the invention would be especially useful in applications requiring assay conditions that would destroy or dramatically reduce the binding affinity and/or specificity of conventional biological sensing elements including but not limited to organic solvents, high or low temperature, acidic or basic solutions and salts.
  • the strategy could be used to discriminate complex samples from other origins including but not limited to, body fluids such as blood, serum, saliva, sputum, urine and the like, thus allowing complex correlations with known reference standards (using pattern recognition programs).
  • Environmental samples such as air, soil, water and the like, food stuffs and the like as well as artificial substances for which appropriate sensing elements can be found could be analysed using this strategy, i.e. appropriate signal to noise ratios can be obtained for the samples in question.
  • No analytical approach can currently exists which can discriminate samples as rapidly or as cost effectively.
  • An important object of the invention is the ability of the strategy to take advantage of as yet unknown recognition functions present in the recognition elements.
  • any recognition element which exhibits the characteristics required by this assay strategy including but not limited to biomolecules such as proteins, lipids, carbohydrates and nucleic acids, modified biomolecules, such as genetically engineered, chemically modified, and the like, as well as synthetic molecules used in molecular recognition, such as cyclodextrans, templated and imprinted polymers and the like, may also be used in this regime.
  • Another object of the invention is the combined approach used to immobilize the biomolecules and included special surfaces (gold), hydrophobic thick-film patterning, self-assembling long chain thiols with terminal carboxylic acid groups and an empirically determined EDC/NHS immobilization protocol. While all of these have been used individually, no immobilization protocol exists which combines these various techniques into a single unified protocol.
  • WO patent 92/19975 describes a method for labelling glycoproteins with a fluorescent molecule in a complex mixture using a carbohydrate specific labelling reagent. This mixture of labelled proteins is separated and the banding pattern analysed using pattern recognition techniques.
  • FIG. 1 a Schematic overview of the immobilization procedure using 8 sensing fields.
  • FIG. 1 b Schematic overview of the immobilization procedure using 2 ⁇ 96 sensing.
  • FIG. 2 Schematic of the fixed angle scanning ellipsometer.
  • FIG. 3 Chart of the animal sera responses.
  • FIG. 4 Chart of the human healthy vs sick responses.
  • FIG. 1 The integrated assay format which combines thick film surface patterning, self-assembling monolayers, efficient coupling chemistries and the biotin-streptavidin.
  • the procedure employs a proprietary teflon based thick-film printing ink (Cel-line, USA) to pattern gold coated silicon wafers or glass combined with self-assembling carboxyl-terminated long chain thiol alkanes onto the exposed gold surfaces.
  • Polished silicon wafers (Wacker Chemie, Germany) or glass were coated with gold by evaporation as described (M ⁇ rtensson, J., Arwin, H. Interpretation of spectroscopic ellipsometric data on protein layers on gold including substrate-layer interactions. (1995) Langmuir 11:963-968.). These surfaces were then patterned with a proprietary hydrophobic coating using thick-film technology (Cell-line, USA). The hydrophobic thick-film patterning greatly simplified localization of the various reagents which lead to a dramatic improvement in the overall reproducibility of the assay protocol. The wafers were sonicated in EtOH prior to being treated with HS—(CH 2 ) 16 —COOH (1 mM in EtOH).
  • Another object of the invention is the combined approach used to immobilize the biomolecules and included special surfaces (gold), hydrophobic thick-film patterning, self-assembling long chain thiols with terminal carboxylic acid groups and an empirically determined EDC/NHS immobilization protocol. While all of these have been used individually, no immobilization protocol exists which combines these various techniques into a single unified protocol.
  • the immobilization procedure was empirically optimized by quantitating the amount of radiolabelled streptavidin or human serum albumin.
  • SA and HSA were radiolabelled using the S 35 protein labeling reagent (SLR) according the manufacturers recommendations (Amersham, UK).
  • SLR S 35 protein labeling reagent
  • HSA was first lightly labeled with biotin, dialyzed and subsequently with SLR.
  • Labeled protein (usually 10 7 cpm/ug protein) was diluted with unlabeled protein and added to the wells.
  • the amount of material immobilized was quantitated using a Fuji Phosphorimager.
  • AFM as well as ellipsometric experiments indicate the surface is extremely uniform.
  • a gold corn size of 20 nm corresponds to an accessible area of 70,000 SA/mm 2 .
  • the a highly reproducible immobilization is absolutely required in order to achieve adequate assay reproducibility and for studying the effects of CRD density gradients.
  • This protocol was used to pattern an array of eight biotinylated lectins: canavalia ensiformis, bandeiraea simplicifolia BS-I, arachis hypogaea, phytolacca americana, phaseolus vulgaris pha-e, artocarpus integrifolia, triticum vulgaris, pisum sativum .
  • Pooled sera from Sheep, Goat, Swine and Human (DAKO, Danmark) were diluted 1:4 in RBST and 5 ⁇ l was added to each well. After an overnight incubation at 4° C., the samples were washed with buffer and then briefly with distilled water (to remove excess salts which disturbed the ellipsometric measurements).
  • the apparatus consisted of a 670 nm diode laser (Melles Griot, Sweden) equipped with an aperture, polarisers and a multi-order quarter-retardation plate, arranged in such a way that plane polarized light fell on the sample surface at an appropriate angle.
  • the reflected light was measured using a photodiode.
  • a computer was used to control the position of the sample and to store data obtained from the photodiode.
  • the size of the light spot from the laser was in the order of 1 mm 2 , thus defining the maximum resolution.
  • the distribution and amount of proteins adsorbed on the surface could then be evaluated or visualized by scanning the sample.
  • the equipment allowed for scan areas up to 20 ⁇ 20 mm with a resolution of up to 200 ⁇ 200 pixels.
  • the experimental arrangement is schematically shown in FIG. 2 .
  • the raw values obtained from the experiments were treated with the image analysis program Transform (Spyglass, U.S.A.) or NIH Image to quantitate the data.
  • FIG. 3 The data obtained from one such experiment is shown in FIG. 3 .
  • This data was input into a three layer artificial neural network consisting of 8 nodes corresponding to the 8 lectins.
  • the untreated raw data was input and training quickly lead to convergence, that is to say the net was able to discriminate between the sample.
  • the running conditions were 2 ⁇ l/min, at 25° C. and the running buffer was HBST.
  • the binding of the SA and biotinylated lectins was performed by sequentially injecting 4 ⁇ l of a 50 ⁇ g/ml solution of each.
  • the human sera were obtained from the Infectious Diseases Department at Lunds University Hospital.
  • the reference sera were taken from healthy volunteers (20 individuals).
  • the sick sera samples (8 individuals) all been identified as having clinical bacterial infections.
  • the sera were diluted 4:1 with HBST and 30 ⁇ l was injected. After, completion of the injection, a value was taken in reference units (RUs).
  • the surface was regenerated down to the biotin by injecting regeneration solution. SA and biotinylated lectin were then injected sequentially to begin the next binding study. This process was repeated until all of the serum samples had been analysed by all eight lectins. The results from one such experiment are shown in FIG. 4 . Seven out of the eight sick individuals can be clearly identified as sick when compared with the healthy reference serum samples.

Abstract

Described is a method for discriminating complex biological samples using an array of discrete biological sensing elements immobilized onto a solid support in which constituents bound to the sensor array is directly determined by measuring the mass increase on the surface; data analysis of said method is performed using neutral network or statical based pattern recognition techniques. In a preferred embodiment the liquid sample is tested for the presence of soluble constituent(s) by contacting said sample with said sensor array under specific conditions, removing unbound sample constituent(s), determining the mass increase on the surface and comprising said mass increase data with a reference standard using pattern recognition software.

Description

    SUMMARY OF THE INVENTION
  • The invention takes advantage of the ability of neural, network and statistical software to analyse complex patterns generated using arrays of discrete sensing elements with intermediate affinities and specificities (broad specificity) as a strategy for complex sample discrimination. Discrete sensing elements with appropriate affinities and specificities are chosen such that each element in the array has an acceptable signal to noise ratio. The informational content obtained from this assay strategy would be meaningless if analysed using conventional methods, i.e. positive vs negative type analysis. Accordingly, a pattern recognition based data analysis procedure is employed using, but not limited to, neural network and statistical software must be developed and/or adapted must be employed in order to be able to discriminate complex samples. Pattern recognition forms the basis for the discrimination process that takes full advantage of the increased informational content of this diagnostic strategy.
  • Thus, instead of quantitating the exact amount of a known compound that has bound to a specific sensing element (as is the case in conventional diagnostics), the bound material is quantitated by determining the increase in thickness or mass on the surface of the sensor. This can be accomplished using a number of nonlabel detection principles including, but not limited to, quartz crystal microbalances, optical techniques such as optoaucostics, reflectometry, ellipsometry and surface plasmon resonance (SPR). An essential aspect of the strategy is the fact that the constituents bound to the sensing elements need not be identified to perform the assay. This makes it possible to use recognition elements with complex interactions such as those found in nature. The samples are discriminated by correlating the values from the entire array using pattern recognition and compared to a reference sample. This increases the speed and reduces the time required to perform assays, thereby reducing costs all of which are objects of this invention.
  • In one embodiment of the invention, arrays of lectins are used in combination with neural network analysis as a diagnostic tool to discriminate complex samples, such as serum samples. Lectins are immobilized onto discrete areas in an array onto planar gold coated surfaces using empirically developed high density immobilization protocols. This embodiment of the invention takes advantage of the ability of lectins to recognize saccharides, oligosaccharides and other as yet unknown ligands both natural and synthetic which have an affinity for lectins, free or attached to proteins (glycoproteins), lipids (glycolipids) and other biomolecules. The ubiquitous presence of carbohydrates in all living organisms provides a nearly universal means for identification of complex biological samples. The complex biosynthetic pathways used to synthesize these carbohydrates are effected by subtle changes in their environment. These changes lead to a series of complex global modifications in the composition and thereby the structure of the carbohydrates.
  • This invention takes advantage of this diversity in order to increase the amount of information that can be obtained, instead of quantitating the exact amount of a particular compound that has bound to a specific lectin as is routinely done in conventional diagnostics. The use of arrays of lectins enables the identification of global changes in complex samples, thereby allowing discrimination. We assume many different substances with a wide range of affinities for a particular sensing element are competing for the recognition sites on the lectins. An additional object of the invention is the ability of the assay strategy to take advantage of as yet unidentified recognition capabilities present on biomolecules. These unidentified recognition elements will provide information that allow the discrimination of samples with unprecedented accuracy and presently not possible with any other diagnostic assay strategy. This complex interplay provides a wealth of data which, due to the rapid development in computer technology and signal processing techniques, can be rapidly analysed. Moreover, the ability of sensing element arrays will grow dramatically as more biomolecules are tested in the assay and their unknown recognition functions become evident.
  • An application of this invention involves the use of lectin arrays to discriminate sera from different animal species. In these studies, the constituent(s) bound to each lectin in the array is quantitated using a fixed angle ellipsometer. The responses obtained from these experiments were used to train the artificial neural network. Using appropriate normalization methods, the resulting trained network was able to discriminate all of the serum samples. The assay shows the utility of the invention for the general identification of complex biological material. Another application of the lectin affinity array was for the discrimination of “healthy” and “sick” individuals (humans). These experiments show, that even subtle changes in serum composition such as those associated with mild bacterial infections can be identified (using artificial neural networks with appropriate normalization). In these experiments, the substance(s) bound to the lectins were quantitated using the SPR detection principle. This shows that sample discrimination is not dependent upon a particular nonlabel technique but is universally applicable to any detector that is capable of unloosing substances bound to the sensing elements in nonlabel modes.
  • BACKGROUND OF THE INVENTION
  • Chemical sensor arrays can be used to identify and classify complex gas mixtures or odors (Shurmer, H. V., An electronic nose: A sensitive and discriminating substitute for a mammalian olfactory system, IEEE proc. G 137, 197-204, 1990; Gardner, J. W. and Bartlett, P. N. (eds), Sensors and Sensory Systems for an Electronic Nose, Proc. NATO Advances Research Workshop, Reykjavik, 1992.). Chemical sensors are in general non-specific, but have different selectivity patterns towards the species in the odor. More specifically, it has been demonstrated how large sensing surfaces consisting of different catalytic metals in metal-oxide-semiconductor field effect structures can be used together with an optical evaluation technique to obtain visually identifiable images of odors (I. Lundström, R. Erlandsson, U. Frykman, E. Hedborg, A. Spetz, H. Sundgren, S. Welin, and F. Winquist, Artificial ‘olfactory’ images from a chemical sensor using a light-pulse technique Nature, 352, 47-50, 1991. It is important to note that this increased informational content is derived from the (continuous) varying selectivity profile along the sensing surface for the sensor array. No discrete recognition elements are known to exist. Different pattern recognition methods based on statistical approaches or artificial neural networks can be used to evaluate the signal patterns from these sensors. The devices have been used to analyze a variety of food stuffs (Winquist, F., Hörnsten, E. G., Sundgren, H. and Lundström, I., Performance of an electronic nose for quality estimation of ground meat, Meas. Sci. Technol. 4, 1493-1500, 1993.; Winquist, F., Hörnsten, G., Holmberg, M., Nilsson, L. And Lundström, I. Classification of bacteria using a simplified sensor array and neural nets”, submitted).
  • New sensor concept. The analogy between these sensors and that of biological sensing systems, such as the olfactory system, has been conceptually important in driving the development of this technology. The basis for the human olfactory sense is that a signal pattern is generated from the receptors cells in the olfactory bulb. The receptor cells are not specific for a particular molecules, but rather belong to different selectivity classes. The basis for olfaction (smell) appears to combine the signals obtained from each of the low specificity receptor classes. The combinatorial effect that results leads to an increase in the discriminatory ability of the system (despite the relatively small number of receptor classes). The chemical sensing elements can recognize odors but lack the discrete recognition capabilities that biomolecules and synthetic biomimetic molecules possess. As noted, chemical sensors use continuous gradients and other approaches as recognition elements and are not discrete. Nature uses discrete identifiable sensing elements which have evolved recognition capabilities in a biological context. One object of the invention is to apply discrete biosensing elements in a fashion that increases the informational content of the diagnostic assay. This would require the employment of a biomolecule with broad recognition characteristics which would normally be considered too ill-defined to be useful in conventional diagnostics. The specificity must be chosen so as to obtain adequately broad binding (high informational content) but not so much as to make differentiation between specific and nonspecific binding impossible, i.e. adequate signal to noise ratio. At the same time, biological sensing elements must have well defined binding characteristics that are appropriate for this assay strategy.
  • The invention described here involves the development of a new assay strategy for complex sample discrimination using arrays of biorecognition elements that is far more informationally rich than conventional assays. Another object of this invention is to reduce the number of tests that must be performed before a diagnosis can be made, thereby reducing the time required to start treatment as well as the cost. Unlike standard diagnostic tests which detect known compounds highly specifically, we detect the binding of unknown compounds to the lectins. Thus, the new assay strategy requires the employment of specialized nonlabel-based detection techniques, including but not limited to quartz crystal microbalances and optical techniques such as optoaucostics, reflectometry, ellipsometry and surface plasmon resonance (SPR). All of the methods that are based on polarized light reflected off a solid surface have already proven valuable for thickness determination of proteins on solid surfaces. The sensitivity of the methods are about the same, which is on the order of a few ångströms.
  • Biological sensing elements. Proteins have the ability to combine specifically and reversibly with a variety of ligands. Enzymes for example bind substrates and inhibitors while antibodies can be produced which bind a variety of antigens such as carbohydrates, proteins, and small molecules. Another class of proteins, lectins, have the ability to bind sugars and are devoid of enzymatic activity. Receptors bind a wide range of ligands with high affinity and specificity. Nature evolves and maintains proteins for specific purposes with adequate affinity and specificity for a particular purpose. Thus, the employment of biological or synthetic biomimetic sensing elements is the most appropriate approach for identifying changes that are of biological significance. We have chosen to test the biosensing affinity arrays invention described here using the lectins. We shall describe lectins and give several advantages this class of proteins has over the more commonly used immune-based diagnostics in the application of this invention.
  • Lectins as biological recognition elements. As mentioned previously, lectins bind carbohydrates and to compounds with similar structure. (Lectins as molecules and as tools. Lis, H. And Sharon, N. Ann. Rev. Biochem., 55, 35-67, 1986; Advances in Lectin Research. Vol 1, Franz, H. Ed., Springer-Verlag, Berlin, 187 pp., 1987). Lectins also have the capability to agglutinate cells, precipitating polysaccharides and glycoproteins and are of nonimmune origin. This is due to the fact that they are oligomeric in structure, usually containing one sugar binding site per subunit. In this respect, lectins have agglutinating abilities similar to those of antibodies. They also can be inhibited by low molecular weight compounds, which in the case of lectins are small carbohydrates, such as monosaccharide, oligosaccharides or macromolecules which contain them.
  • First, lectins provide a broad spectrum of well defined binding specificities with a high degree of cross reactivities as compared for example with antibodies and enzymes. Furthermore, they are stable and have a wide range of affinities and specificities. In addition, over one hundred lectins have been characterized. It now appears that lectins mediate a variety of cellular interactions during development and in the adult animal (Drickamer, K. And Taylor, M. E. Biology of Animal Lectins Annu. Rev. Cell Biol. 9:237-64, 1993). This is supported by data which shows that lectin expression patterns change throughout development and in response to a wide range of environmental changes [Varki, A. Biological roles of oligosaccharides: all of the theories are correct, Glycobiology, 3:97-130, 1993.]. The involvement of oligosaccharides in selectin-mediated cell-cell recognition by the immune system in response to inflammation [Lasky, L. A. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science 258:964-969, 1992 and sperm-cell recognition during fertilization [Miller, D. J., Macek, M. B., Shur, B. D. Complementarity between sperm surface b1,4-galactosyltransferase and egg coat ZP3 mediates sperm-egg binding. Nature 357:589-593, 1992) are but a few examples. It is also known that modifying the expression of glycosides and glycosyltransferases interferes with normal development. However, it has not been possible to define the individual contributions of individual monosaccharides residues and oligosaccharide chains to stage-specific and tissue-specific developmental processes.
  • An object of this invention is the ability of the assay strategy to discriminate complex samples which could be used to delineate complex basic developmental processes.
  • Second, the study of lectins is intimately linked to that of carbohydrates and is referred to as glycobiology (Glycoproteins, Hughes, R. C. outline Studies in Biology, Chapman and Hall, London and New York, 95 pp, 1983). Glycosylation is used extensively in nature for a wide range of purposes some general, such as protease protection, some directed to particular classes of proteins, such as signaling mechanism for clearance of proteins from serum and some highly specific, such as cell adhesion. Carbohydrates also act as control mechanisms, as signals for cellular localization, for specific cell surface recognition of one cell type by another, for clearance of a particular glycoform from serum, assist in protein folding possibly by providing protection against proteolysis (Pareth, R. B. Effects of glycosylation on protein function. CUM Opin. Struct. Biol. 1:750-54, 1991).
  • Carbohydrates contain a potential informational content several orders of magnitude greater than any other biological oligomer. For example, if one calculates the number of possible structures for a hexamer of sugars and that of a hexamer of amino acids, the figure is >1.05×1012 and 4.6×101. The difference is more than seven orders of magnitude. Accordingly, sugars clearly provide the largest single source of diversity in the biological world (Laine, R. A. Invited Commentary in Glyco-Forum section Glycobiology 1994 8, 759-767).
  • Lectins have also been shown to be important in defense against a variety of pathogens. The mannose binding lectins in animals mediates antibody-independent binding of pathogens which contain a high concentration of mannose on their surface. These monosaccharides are not generally found in terminal positions on serum or cell surface glycoproteins in mammalian systems. The recognition event can initiate the complement cascade [Ikeda, K, Sannoh, T., Kawasaki, T. And Yamashima, I. (1987) J. Biol. Chem. 262, 7451-7454.]. Plant lectins have also been implicated in attachment of symbiotic nitrogen fixing bacteria to the roots of leguminous plants and int eh protection of plants against fungal pathogens (Bohlool, B. B. and Schmidt, E. L. (1974) Science 185:269-71).
  • Third, numerous pathogens use carbohydrate-lectin interactions in order to gain entry into their hosts. For example, bacteria and intestinal parasites, such as amoeba, mediate the sugar specific adherence of the organisms to epithelial cells and thus facilitate infection. (Liener, I. E., Sharon, N., Goldstein, I. J. eds (1986) The Lectins: Properties, functions and applications in biology and medicine. New York: Academic.). Viruses such as influenza virus (myxovirus) and Sendia virus (paramyxovirus) use a haemagglutonin protein that binds sialic acid containing receptors on the surface of target cells to initiate the virus-cell interaction (Paulsson, J. C. Interaction of animal viruses with cell surface receptors. in: The Receptors (Vol. 2) (ed. P.M. Conn), Academic Press, New York, pp. 131-219, 1985).
  • Another object of the invention is to study the pathogenesis of diseases that use carbohydrates or lectins in order to gain entry into cells.
  • Carbohydrate binding proteins such as selectins are believed to play a critical role in immune responses including inflammation (Springer, et al. 1991 Nature 349:196-197; Philips, et al., 1990 Science 250:1130-32. Specific carbohydrate ligands have been identified and have been used to control inflammation, immunosuppression, etc. through their interaction with selectin proteins and/or other lectins (Gaeta, et al., U.S. patent application Ser. No. 07/538,853, filed 15 Jun. 1990; Ippolito, et al., U.S. patent application Ser. No. 07/889,017, filed 26 May 1992). Other glycoproteins have also been shown to be useful in suppressing mammalian immune responses (Smith et al., U.S. patent application Ser. No. 07/956,043 filed 2 Oct. 1992).
  • Another object of the invention is to use the assay strategy in order to delineating the more subtle recognition functions of lectins, including but not limited to selectin and other lectins, in immune and inflammatory responses.
  • Fourth, the wide distribution of and ready availability of large numbers of sugars and sugar binding proteins combined with their ubiquity throughout nature, has led to their extensive use as reagents for studying carbohydrates in solution and on cell surfaces. They were originally used for blood typing (Lis and Sharon), for the identification and separation of cells (Sharon, N. 1983 Adv. Immunol. 34:213-98). Labelled lectins serve as specific reagents for the detection of glycoproteins separated on gels, either directly or after blotting (Rohringer, R., Holden, D. W. 1985 Anal. Biochem. 144:118-27.) Immobilized lectins are routinely used for isolating glycoproteins such as the insulin receptor (Hedo; J. A., Harrison, L. C., Roth, J. 1981 Biochemistry 20:3385-93) and the many others proteins. Lectins have been widely used to separate cells such as thymocytes and splenocytes (Reisner, Y, Sharon, N. 1984 Methods Enzymol. 108:168-79; Maekawa, M., Nishimune, Y. 1985 Biol. Reprod. 32:419-25.). Numerous bacteria have been typed using lectins (Doyle, R. J., Keller, K. F. 1984 Can. J. Microbiol. 3:4-9; DeLucca, A . J. II 1984 Can. J. Microbiol. 3:1100-4). Primates can be differentiated from non-primates by the presence of specific sugar residues [Spiro, R. G. and Bhoyroo, V. D. (1984) J. Biol. Chem. 259, 9858-9866; Galili, U., Shohet, S. B., Kobrin, E. Kobrin, E., Stults, C. L. M., and Macher, B. A. (1988) J. Biol. Chem. 263, 17755-17762. These applications are strictly dependent upon the ability of a particular lectin to specifically identify a carbohydrate attached either to a soluble biomolecule or to a cell or organelle.
  • Fifth, most cells have a coating of carbohydrate chains in the form of membrane glycoproteins and glycolipids (in eukaryotes) or of polysaccharides (in prokaryotes). In eukaryotes, the cell type and environmental factors such as glucose concentration, play a major role in determining the extent and type of glycosylation, which is both species and tissue specific (Parekh, R. B., Dwek, R. A., Thomas, J. R., Opdenakker, G., Rademacher, T. W. (1989) Biochemistry 28, 7644-7662; Goochee, C. F. and Monica, T. (1990) Bio/Technology 8, 421-427). In addition, each individual enzymatic reaction may or may not go to completion, giving rise to glycoforms or glycosylated variants of the protein (Rademacher, et al. Ann. Rev. Biocehm., 1988 57:789-838). These factors give rise to the enormous heterogeneity of carbohydrate structures, found in vivo that has hindered their analysis. However, in some instances the relative concentration of the different forms have been shown to vary in specific ways in certain health and disease states. For example This also explains why glycosylation patterns of natural glycoproteins may be influenced by physiological changes such as pregnancy and also diseases such as rheumatoid arthritis.
  • In addition, it is known that the interaction between individual monosaccharides and CRDs is too weak to account for the affinities that lectins have for glycoproteins. The oligomeric lectins (multivalent) clusters the carbohydrate recognition domains (CRDs) which increases both the specificity and the affinity for multibranched oligosaccharides. While these effects are not well understood, it is clear that the density of CRD has biological significance. Thus, is an additional parameter that can be used in the invention to further increase the informational content of the assay. This would indicate that lectins could be useful following changes in the overall state of complex biological samples. This wealth of diversity provides a nearly unlimited range of sensor elements from which to choose.
  • It is believed that the multivalency of lectins for carbohydrates is important for their biological activity. Thus, an object of the invention would be the application of density gradients of lectins on surfaces in continuos and discontinuous, as well as in homogeneous and heterogeneous formats for sample discrimination. This would provide a unique tool for gaining a basic understanding of the effect of binding site density on the recognition process. Methods are available to those skilled in the art for adapting reflectometry, ellipsometry or SPR for scanning and imaging modes. This also would provide an additional assay parameter, thus increasing the informational content of the lectin affinity arrays and thereby improving their ability to discriminate complex samples.
  • Diagnostic assays strategies. Immunoassay based diagnostics currently predominate the market, nevertheless, lectins provide some advantages over conventional immunoassays. Lectins are present in most life forms and more importantly they are found in life forms such as plants, microorganisms and viruses, which do not synthesize immunoglobulin. Clearly the biological function(s) of lectins precedes that of the immune system, many of which are unknown at present. Thus, these sensing elements will be more useful for identification and classification purposes. The extensive homologies observed between different classes of lectins demonstrate that these proteins have been conserved throughout evolution and provide strong evidence that they have important function(s) in biology. Another difference is that lectins are structurally diverse whereas antibodies are structurally similar. This structural diversity would result in a corresponding diversity of stabilities that would increase the flexibility of the assay formats (antibodies tends to denature under similar conditions due to their structural similarity). Thus, lectins combine the multivalency of antibodies with the structural diversity of enzymes. Other proteins which bind carbohydrates also exist such as those that participate in carbohydrate metabolism and sugar transport. In general, these proteins only bind one carbohydrate and serve quite different purposes than lectins.
  • The detection of specified antigens, haptens and the like substances in bodily fluids such as blood, serum, sputum, urine, and the like is of central importance in both research and clinical environments. The detection of such ligands can often be correlated to various disease states and consequently, is of great importance in diagnosis and for gaining a basic understanding concerning the genesis of disease, as well as for monitoring the efficacy of therapeutic treatments. The large and ever increasing ability to diagnose and treat diseases has lead to an explosive increase in demand for diagnostic testing. And while the cost per assay has been reduced, the number of tests that are performed has increased dramatically. This is in part due to the increasing number of tests that are available and in part due to the need medical practitioners have to be able to justify their actions in the event that legal action (malpractice suits) should be taken against them.
  • Accordingly, improved methods for detecting ligands in aqueous samples are constantly being sought. In particular, such preferred methods or assays are those that are faster, more flexibility, simpler to perform and manufacture, as well as having low manufacturing costs. In addition, there is an increasing need for strategies that will reduce the time necessary to develop diagnostic assays for such agents as HIV and Bovine Spongiform Encephalitis (B SE). Increasing health costs require the development of new, rapid, and more effective diagnostic strategies.
  • In general, immunoassays are based upon the immunological reaction between proteins such as antibodies, antibody fragments, or even artificially generated elements simulating antibody binding sites such as peptides, templated polymers and the like (hereafter referred to as antibody recognition) and the substance for which they are specific, the ligand. Immunological reactions are characterized by their high specificity and accordingly, numerous schemes have been developed in order to take advantage of this characteristic. The goal is to identify a particular state with absolute specificity using as few assays as possible.
  • In the traditional heterogeneous forward assay, an antibody is immobilized on a solid phase such as microparticles, microtiter wells, paddles, and the like. The sample is then contacted with the immobilized antibody and the ligand binds if present in the sample. The bound substance is detected and quantitated by an entity associated directly or indirectly therewith. Such detectable entity include fluorescent molecules, chemiluminescent molecules, enzyme, isotopes, microparticles and the like. Many variants have been developed such as competition, indirect competition, and the like. Various methods are available to those skilled in the art for quantitating the amount of substance bound using these assays.
  • In addition to immunoassays, other diagnostic assays are available based upon the same demand for absolute specificity using wide range of recognition elements such as proteins (lectins, receptors, and the like), nucleic acids, carbohydrates, lipids and/or synthetic/engineered biomimetic compounds and the like. A wide range of basic techniques have also been developed including but not limited to microscopy, chromatography and electrophoresis in order to specifically identify diseases.
  • It is an object of this invention to provide an assay strategy for sample discrimination which relies upon an array of sensing elements with low specificity in order to increase the informational content of the diagnostic assay. The assay strategy is capable of discriminating subtle changes and thus allows early identification of changes in the state of health that can be of crucial importance. In some instances, the sensing elements used in conventional assays will be applicable. However, in most instances the specificity of these reagents will be too high to allow their use. Accordingly, new screening procedures will be developed in order to isolated reagents with appropriate combination of affinities and specificities and is an object of this invention, as well.
  • The assay strategy can be extended to a wide range of applications that require complex sample discrimination including but not limited to identification of diseases, identification of changes caused by the disease itself in the host (including but not limited to human, animal, plants and microorganisms). Complex samples containing biological material and/or degradation products including but not limited to such as food stuffs like beverages, dry foods, and the like (including but not limited to quality control, for detection of unwanted microbial growth, freshness, physical damage), as well as the control of environmental samples for microbial flora (including but not limited to microbial content and composition), pollutants and their breakdown products in air, soil and water samples. This strategy and assays based on it could also be used for monitoring fermentation processes, including but not limited to yogurt, beer, wine and the like, broths, as well as in fermentation processes in which products are produced such as biological compounds produced by microbial processes, such as insulin from genetically engineered bacteria and the like, as well as condiments made for seasoning and the like, as well fermentation processes used in the production of animal food stuffs.
  • Current diagnostic testing approaches used to determine the general state of health such as hemoglobin, blood pressure and the like give only limited information. And while these tests provide useful information as to the general state of health, they do not provide adequate information to identify diseases nor are they sensitive enough to detect subtle changes required for early disease detection. There is a need, therefore, to develop new strategies for the identification of disease states which provide information as to which class of ailments the patient is suffering in order to reduce the number of specific tests which must be performed.
  • Another object of the invention is to provide a strategy and assays for improved techniques to monitor the general state of health to assist efforts in identifying ailments early on thereby allowing treatment to begin at an earlier stage than would have been possible otherwise. The early treatment of disease has been shown to reduce health care costs. This strategy would also be useful in preventative health care schemes. A similar situation exists in food stuff and environmental testing.
  • This diagnostic strategy based on the use of discrete recognition elements with broad recognition specificities combined with computer based artificial neural network data analysis can also be used with discrete synthetic biomimetic recognition elements with appropriate specificity (signal to noise). These could be made from modified biological material or from polymeric materials by conventional templating techniques and the like. This embodiment of the invention would be especially useful in applications requiring assay conditions that would destroy or dramatically reduce the binding affinity and/or specificity of conventional biological sensing elements including but not limited to organic solvents, high or low temperature, acidic or basic solutions and salts.
  • These detection techniques demand highly reproducible, high density immobilization methods for flat surfaces such as silicon wafers or flat glass. Other surfaces compatible with these detection techniques including but not limited to plastic, silicon, mica and glass surfaces in both metal coated or uncoated. Standard immobilization protocols resulted in poor overall reproducibility due to inadequate signal to noise ratios. A method was developed that allowed high density immobilization of biomolecules with high retention of biological activity while minimizing nonspecific binding assay. The increased sensitivity and reduced nonspecific binding achieved increased the signal to noise ratio that was essential for this assay strategy. We now believe that the nearly 100% surface coverage. This prevents interaction directly with the metal surface, and provides an essentially homogenous interaction matrix, and maximizes surface densities.
  • The strategy could be used to discriminate complex samples from other origins including but not limited to, body fluids such as blood, serum, saliva, sputum, urine and the like, thus allowing complex correlations with known reference standards (using pattern recognition programs). Environmental samples such as air, soil, water and the like, food stuffs and the like as well as artificial substances for which appropriate sensing elements can be found could be analysed using this strategy, i.e. appropriate signal to noise ratios can be obtained for the samples in question. No analytical approach can currently exists which can discriminate samples as rapidly or as cost effectively. An important object of the invention is the ability of the strategy to take advantage of as yet unknown recognition functions present in the recognition elements.
  • We have not made any attempt to identify the substances bound to the lectin arrays but various methods are available to those skilled in the art of identifying biomolecules to perform this type of analysis. While this is not the primary aim of the invention, it may prove useful for understanding the nature of changes that have occurred that may assist in the development of therapies and/or the development of therapeutic drugs. In addition, any recognition element which exhibits the characteristics required by this assay strategy, including but not limited to biomolecules such as proteins, lipids, carbohydrates and nucleic acids, modified biomolecules, such as genetically engineered, chemically modified, and the like, as well as synthetic molecules used in molecular recognition, such as cyclodextrans, templated and imprinted polymers and the like, may also be used in this regime.
  • Another object of the invention is the combined approach used to immobilize the biomolecules and included special surfaces (gold), hydrophobic thick-film patterning, self-assembling long chain thiols with terminal carboxylic acid groups and an empirically determined EDC/NHS immobilization protocol. While all of these have been used individually, no immobilization protocol exists which combines these various techniques into a single unified protocol.
  • Numerous patents have been disclosed which employ a wide range of biological sensing elements for diagnostic and therapeutic purposes, such as WO 95/29692, WO 95/15175, WO 95/28962, WO 95/07462, Canadian patent 2,133,772, U.S. Pat. No. 4,289,747, U.S. Pat. No. 4,389,392, U.S. Pat. No. 4,298,689 and WO 95/26634. All of these inventions use the unique specificity of some sensing element, be it an antibody or a lectin, to identify a single disease (or groups of highly related diseases). Great attempts are made to increase the specific reaction and reduce the nonspecific reactions, in strong contrast to the invention described here.
  • WO patent 92/19975 describes a method for labelling glycoproteins with a fluorescent molecule in a complex mixture using a carbohydrate specific labelling reagent. This mixture of labelled proteins is separated and the banding pattern analysed using pattern recognition techniques.
  • Our invention has several advantages over this invention. First, no separation steps are involved which reduces the time, labour, cost and complexity of the assay. Second, no recognition elements are used, limiting the flexibility of the assay. Third, since no recognition elements are used the analysis of known or unknown binding functions is not possible. And finally, the assay cannot be expanded which restricts the ability of the assay to take full advantage of pattern recognition programs.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 a. Schematic overview of the immobilization procedure using 8 sensing fields.
  • FIG. 1 b. Schematic overview of the immobilization procedure using 2×96 sensing.
  • FIG. 2. Schematic of the fixed angle scanning ellipsometer.
  • FIG. 3. Chart of the animal sera responses.
  • FIG. 4. Chart of the human healthy vs sick responses.
  • DETAILED DESCRIPTION OF THE INVENTION Example 1
  • Interfacing these biological sensing elements with the surface mass based optical imaging technology was very difficult. Standard immobilization protocols resulted in poor overall reproducibility and lead us to develop a highly specialized protocol which combines surface patterning and immobilization technologies (FIG. 1). The integrated assay format which combines thick film surface patterning, self-assembling monolayers, efficient coupling chemistries and the biotin-streptavidin. The procedure employs a proprietary teflon based thick-film printing ink (Cel-line, USA) to pattern gold coated silicon wafers or glass combined with self-assembling carboxyl-terminated long chain thiol alkanes onto the exposed gold surfaces. Polished silicon wafers (Wacker Chemie, Germany) or glass were coated with gold by evaporation as described (Mårtensson, J., Arwin, H. Interpretation of spectroscopic ellipsometric data on protein layers on gold including substrate-layer interactions. (1995) Langmuir 11:963-968.). These surfaces were then patterned with a proprietary hydrophobic coating using thick-film technology (Cell-line, USA). The hydrophobic thick-film patterning greatly simplified localization of the various reagents which lead to a dramatic improvement in the overall reproducibility of the assay protocol. The wafers were sonicated in EtOH prior to being treated with HS—(CH2)16—COOH (1 mM in EtOH). The surfaces were rinsed with EtOH, then sonicated in EtOH and finally rinsed again in EtOH. The surface was then activated using NHS (0.2M) and EDC (0.8M) in distilled water for 60 min at room temperature. The surface was briefly rinsed with distilled water and blown dry with nitrogen gas. Amino-biotin (Molecular Probes, USA) was added (1 mM in 100 mM carbonate buffer, pH 8.5) and incubated at room temperature for 60 min. After briefly rinsing the surface with distilled water, 50 ug/ml streptavidin (Molecular Probes) in HBST (150 mM NaCl, 0.1% tween 20 and 20 mM Hepes, pH 7.4) and incubated 30 minutes at RT. The surface was washed and 50 ug/ml (diluted in HBST) of the biotinylated biomolecule of choice was applied to the appropriate and incubated for 60 min at RT. An overview is shown in FIG. 1.
  • Another object of the invention is the combined approach used to immobilize the biomolecules and included special surfaces (gold), hydrophobic thick-film patterning, self-assembling long chain thiols with terminal carboxylic acid groups and an empirically determined EDC/NHS immobilization protocol. While all of these have been used individually, no immobilization protocol exists which combines these various techniques into a single unified protocol.
  • The immobilization procedure was empirically optimized by quantitating the amount of radiolabelled streptavidin or human serum albumin. SA and HSA were radiolabelled using the S35 protein labeling reagent (SLR) according the manufacturers recommendations (Amersham, UK). For the double labeling HSA was first lightly labeled with biotin, dialyzed and subsequently with SLR. Labeled protein (usually 107 cpm/ug protein) was diluted with unlabeled protein and added to the wells. The amount of material immobilized was quantitated using a Fuji Phosphorimager. The protocol was highly reproducible (n=10, S.D.=5%). Surface density calculations and other evidence indicate that SA is present as a tight monolayer on the surface. AFM as well as ellipsometric experiments indicate the surface is extremely uniform. In addition, we have calculated the SA packing density to be 60,000 SA/mm2 using the radiolabelling data. This is 20% higher than the theoretical packing of 50,000 SA/mm2 and can be accounted for by the roughness of the gold surfaces used in these experiments. A gold corn size of 20 nm (determined from atomic force microscopy of the surfaces) corresponds to an accessible area of 70,000 SA/mm2. The a highly reproducible immobilization is absolutely required in order to achieve adequate assay reproducibility and for studying the effects of CRD density gradients.
  • This protocol was used to pattern an array of eight biotinylated lectins: canavalia ensiformis, bandeiraea simplicifolia BS-I, arachis hypogaea, phytolacca americana, phaseolus vulgaris pha-e, artocarpus integrifolia, triticum vulgaris, pisum sativum. Pooled sera from Sheep, Goat, Swine and Human (DAKO, Danmark) were diluted 1:4 in RBST and 5 μl was added to each well. After an overnight incubation at 4° C., the samples were washed with buffer and then briefly with distilled water (to remove excess salts which disturbed the ellipsometric measurements). The samples were then placed on the XY stage of a scanning fixed angle ellipsometer which was build at the Laboratory of Applied Physics (Arwin, H., Lundström, I. Surface oriented optical methods for biomedical analysis. (1988) Method in Enzymology 137:366-381; Jin, G., Tengvall, P., Lundström, I., Arwin, H. (1995) Applications of imaging ellipsometry for antigen-antibody binding studies. (1996) Analytical Biochemistry, in press). The apparatus consisted of a 670 nm diode laser (Melles Griot, Sweden) equipped with an aperture, polarisers and a multi-order quarter-retardation plate, arranged in such a way that plane polarized light fell on the sample surface at an appropriate angle. The reflected light was measured using a photodiode. A computer was used to control the position of the sample and to store data obtained from the photodiode. The size of the light spot from the laser was in the order of 1 mm2, thus defining the maximum resolution. The distribution and amount of proteins adsorbed on the surface could then be evaluated or visualized by scanning the sample. The equipment allowed for scan areas up to 20×20 mm with a resolution of up to 200×200 pixels. The experimental arrangement is schematically shown in FIG. 2. The raw values obtained from the experiments were treated with the image analysis program Transform (Spyglass, U.S.A.) or NIH Image to quantitate the data.
  • The data obtained from one such experiment is shown in FIG. 3. This data was input into a three layer artificial neural network consisting of 8 nodes corresponding to the 8 lectins. In the first run, the untreated raw data was input and training quickly lead to convergence, that is to say the net was able to discriminate between the sample.
  • Example 2
  • In these studies, sick vs healthy human serum samples were analysed using the same array of eight biotinylated lectins: canavalia ensiformis, bandeiraea simplicifolia BS-I, arachis hypogaea, phytolacca americana, phaseolus vulgaris pha-e, artocarpus integrifolia, triticum vulgaris, pisum sativum. In this case, unpatterned gold (50 nm thick gold evaporated by sputtering) coated glass (0.3 mm thick glass) surfaces were prepared essentially as described above up to and including the coupling of amino-biotin. The surfaces were then inserted into the BIAcore from Pharmacia Biosensor. The running conditions were 2 μl/min, at 25° C. and the running buffer was HBST. The binding of the SA and biotinylated lectins was performed by sequentially injecting 4 μl of a 50 μg/ml solution of each.
  • The human sera were obtained from the Infectious Diseases Department at Lunds University Hospital. The reference sera were taken from healthy volunteers (20 individuals). The sick sera samples (8 individuals) all been identified as having clinical bacterial infections. The sera were diluted 4:1 with HBST and 30 μl was injected. After, completion of the injection, a value was taken in reference units (RUs). The surface was regenerated down to the biotin by injecting regeneration solution. SA and biotinylated lectin were then injected sequentially to begin the next binding study. This process was repeated until all of the serum samples had been analysed by all eight lectins. The results from one such experiment are shown in FIG. 4. Seven out of the eight sick individuals can be clearly identified as sick when compared with the healthy reference serum samples.
  • We originally intended to use antibodies for these studies. However, we were unable to find monoclonal antibodies with an appropriate combination of affinity and specificity. This could be due to the screening procedure used to select these antibodies or possibly due to suppression of broadly cross-reacting antibodies.

Claims (21)

1. A method for discriminating complex biological samples using an array of discrete biological sensing elements immobilized onto a solid support inwhich constituents bound to the sensor array is directly determined by measuring the mass increase on the surface; data analysis of said method is performed using neural network or statical based pattern recognition techniques.
2. A method for discriminating complex biological samples using an array of discrete biological sensing elements immobilized onto a solid support and testing the liquid sample for the presence of soluble constituent(s) comprising: contacting said sample with said sensor array under conditions wherein said sensing elements permitting binding of constituents in said sample; if any are present; removal of substantially all unbound sample constituents; the direct detection of said bound constituents by determining the mass increase of said components on the surface; comparison of said mass increase data of said sample with a reference standard using pattern recognition software.
3. The method of claim 2 wherein said sensing element is selected from a group consisting of, antibodies, lectins, nucleic acids, carbohydrates, genetically modified derivatives and combinations and gradients thereof.
4. The method in claim 2 wherein said sensing element is of nonbiological origin but is endowed with biological-like recognition selected from the group consisting of cyclodextran and derivatives thereof, roxane and derivatives thereof, templated or imprinted polymers and combinations thereof.
5. The method in any of claims 2 to 4 wherein said immobilization procedure combines the use of gold surfaces, long chain thiol alkanes with terminal activatable groups, hydrophobic/hydrophilic patterning, EDC/NHS coupling amino-biotin and streptavidin.
6. The method in any of claims 2 to 5 wherein said solid support is selected from the group consisting of silicon, glass, mica, plastic, platinum, silver, copper, gold and combinations thereof.
7. The method in any of claims 2 to 6 wherein said surface mass increase detection techniques are selected from the group consisting of quartz crystal microbalances, optoaucostics, reflectometry, ellipsometry, SAW and surface plasmon resonance.
8. The method in any of claims 2 to 7 wherein said surface mass detection is performed in imaging mode with a CCD camera.
9. The method of diagnosing a disease, said method comprising the method in any of claims 2 to 8, wherein said mass increase pattern is diagnostic of the disease, said sample is a patient sample and said standard is the pattern present in an individual without said disease.
10. The method in claim 9 wherein said patient sample is a human or animal, tissue or bodily fluid, selected from the group consisting of blood, serum, urine, milk, sweat, exhaled air, skin, bone marrow, cerebrospinal fluid, synovial fluid, amniotic fluid and lymphatic fluid.
11. The method in claim 9 wherein said disease is selected from the group consisting of genetic disorders, autoimmune diseases, arthritis, infectious diseases, cancer, heart disease, drug abuse and lung disease.
12. The method of diagnosing the general state of health, said method comprising the method in any of claims 2 to 11, wherein said mass increase pattern is diagnostic of a particular state of health, said sample is a patient sample and said standard is the pattern present in a representative part of the population.
13. The method in claim 12 wherein said general state of health is selected from common mild ailments and/or health conditions with diffuse symptoms, consisting of high blood pressure, pregnancy, common colds, injuries, inflammatory reactions, mild immune suppression, doping, altitude sickness, space sickness chronic fatigue syndrome; and effects of low level toxic chemical or radiation exposure, menstrual cycles and subclinical infections.
14. The method of identifying an organism, said method comprising the method in any of claims 2 to 8, wherein said mass increase pattern is unique to a particular organism, said sample is a biological sample from a particular organism and said standard is the pattern normally found in that organism.
15. The method in claim 14 wherein said biological sample is tissue or an extract selected from the group consisting of animals, microorganisms, fungi, viruses, bacteria, plants and protozoa.
16. The method of identifying samples contaminated with toxic compounds, said method comprising the method in any of claims 2 to 8, wherein said mass increase pattern is diagnostic of contaminated material, said sample is a environment sample and said standard is the pattern present in an uncontaminated sample.
17. The method in claim 16 wherein said environmental sample is the untreated or extracted sample selected from the group consisting of air, soil, water, rock, ice, plant, lichen, animal and food stuffs.
18. The method in any of claims 2 to 17 wherein said sensing element array are lectins selected from the group consisting of canavalia ensiformis, bandeiraea simplicifolia BS-I, arachis hypogaea, phytolacca americana, phaseolus vulgaris pha-e, artocarpus integrifolia, triticum vulgaris, pisum sativum.
19. The method in any of claims 2 to 18 wherein said the lectin array is expanded to include additional lectin or lectin-like sensing elements and/or used in combination with other biological sensing elements in a diagnostic assay.
20. The method in any of claims 2 to 8 wherein said sensing elements are used in gradients in pure and mixed formats and in any combination thereof.
21. The method in any of claims 2 to 18 wherein said bound constituents are isolated and used as diagnostic tool, to further the understanding of the disease or to develop a drug or therapy to treat an ailment identified by the said method.
US12/911,125 1996-06-25 2010-10-25 Broad specificity affinity arrays: a qualitative approach to complex sample discrimination Abandoned US20110111973A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/911,125 US20110111973A1 (en) 1996-06-25 2010-10-25 Broad specificity affinity arrays: a qualitative approach to complex sample discrimination

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
SE9602545-7 1996-06-25
SE9602545A SE9602545L (en) 1996-06-25 1996-06-25 Method of discriminating complex biological samples
PCT/EP1997/003317 WO1997049989A2 (en) 1996-06-25 1997-06-24 Broad specificity affinity arrays: a qualitative approach to complex sample discrimination
US09/220,822 US6872522B1 (en) 1996-06-25 1998-12-24 Broad specificity affinity arrays: a qualitative approach to complex sample discrimination
US11/042,984 US7662560B2 (en) 1996-06-25 2005-01-25 Broad specificity affinity arrays: a qualitative approach to complex sample discrimination
US70433410A 2010-02-11 2010-02-11
US12/911,125 US20110111973A1 (en) 1996-06-25 2010-10-25 Broad specificity affinity arrays: a qualitative approach to complex sample discrimination

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US70433410A Continuation 1996-06-25 2010-02-11

Publications (1)

Publication Number Publication Date
US20110111973A1 true US20110111973A1 (en) 2011-05-12

Family

ID=20403185

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/220,822 Expired - Fee Related US6872522B1 (en) 1996-06-25 1998-12-24 Broad specificity affinity arrays: a qualitative approach to complex sample discrimination
US11/042,984 Expired - Fee Related US7662560B2 (en) 1996-06-25 2005-01-25 Broad specificity affinity arrays: a qualitative approach to complex sample discrimination
US12/911,125 Abandoned US20110111973A1 (en) 1996-06-25 2010-10-25 Broad specificity affinity arrays: a qualitative approach to complex sample discrimination

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/220,822 Expired - Fee Related US6872522B1 (en) 1996-06-25 1998-12-24 Broad specificity affinity arrays: a qualitative approach to complex sample discrimination
US11/042,984 Expired - Fee Related US7662560B2 (en) 1996-06-25 2005-01-25 Broad specificity affinity arrays: a qualitative approach to complex sample discrimination

Country Status (9)

Country Link
US (3) US6872522B1 (en)
EP (1) EP1021713B1 (en)
JP (2) JP3865409B2 (en)
AT (1) ATE364839T1 (en)
CA (1) CA2258941A1 (en)
DE (1) DE69737818T2 (en)
ES (1) ES2289760T3 (en)
SE (1) SE9602545L (en)
WO (1) WO1997049989A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100143925A1 (en) * 2008-11-21 2010-06-10 Michael Adler Conjugate complexes for analyte detection
US20100151472A1 (en) * 2008-11-12 2010-06-17 Nodality, Inc. Detection Composition

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262055B2 (en) 1998-08-25 2007-08-28 Gendaq Limited Regulated gene expression in plants
US7285416B2 (en) 2000-01-24 2007-10-23 Gendaq Limited Regulated gene expression in plants
SE9602545L (en) * 1996-06-25 1997-12-26 Michael Mecklenburg Method of discriminating complex biological samples
DE19724787A1 (en) * 1997-06-06 1998-12-10 Biotez Berlin Buch Gmbh Bioche Streptavidin / avidin coated surfaces
AU4850499A (en) 1998-06-29 2000-01-17 Procter & Gamble Company, The Device having fecal component sensor
US6342037B1 (en) 1998-06-29 2002-01-29 The Procter & Gamble Company Device having fecal component sensor
GB9816441D0 (en) * 1998-07-28 1998-09-23 Hartley Frank R Analysis of liquids
DE19900119C2 (en) * 1999-01-06 2001-02-22 Horst Messer Method and device for diagnosing allergic symptoms
IL129835A (en) * 1999-05-06 2008-03-20 Ofer Markman Polysaccharide sequencing and structure determination
US6680377B1 (en) 1999-05-14 2004-01-20 Brandeis University Nucleic acid-based detection
JP4949560B2 (en) * 1999-05-14 2012-06-13 ブランディーズ・ユニバーシティ Nucleic acid based detection
DE19933212A1 (en) * 1999-07-15 2001-02-15 Gpc Biotech Ag Method and device for high-throughput analysis of molecular interactions via surface plasmon resonance
GB9923146D0 (en) * 1999-09-30 1999-12-01 Imperial College Detector array
NZ522859A (en) 2000-06-19 2005-08-26 Correlogic Systems Inc Heuristic method of classifying objects using a vector space having multiple preclassified data clusters
US7518724B2 (en) * 2000-07-11 2009-04-14 Maven Technologies Image acquisition, processing, and display
EP1386275A2 (en) * 2000-07-18 2004-02-04 Correlogic Systems, Inc. A process for discriminating between biological states based on hidden patterns from biological data
AU2002241604B2 (en) * 2000-11-03 2008-01-10 Procognia (Israel) Ltd. System and method for integrated analysis of data for characterizing carbohydrate polymers
US6913697B2 (en) * 2001-02-14 2005-07-05 Science & Technology Corporation @ Unm Nanostructured separation and analysis devices for biological membranes
US20040091938A1 (en) * 2001-02-20 2004-05-13 Tatsuro Irimura Lectins for analyzing sugar chains and method of using the same
KR100558185B1 (en) * 2001-09-21 2006-03-10 주식회사 바이오메드랩 Method of quantitatively measuring protein using surface plasmon resonance
US6870626B2 (en) * 2001-11-13 2005-03-22 Battelle Memorial Institute Array-based photoacoustic spectroscopy
US6999174B2 (en) 2001-11-13 2006-02-14 Battelle Memorial Institute Photoacoustic spectroscopy sample array vessels and photoacoustic spectroscopy methods for using the same
US6873415B2 (en) 2001-11-13 2005-03-29 Battelle Memorial Institute Photoacoustic spectroscopy sample array vessel and photoacoustic spectroscopy method for using the same
JP4109022B2 (en) * 2002-06-13 2008-06-25 富士フイルム株式会社 Measuring device and method of using the measuring device
TW200407543A (en) 2002-07-29 2004-05-16 Correlogic Systems Inc Quality assurance/quality control for high throughput bioassay process
CN1395103A (en) * 2002-07-31 2003-02-05 中华人民共和国北京出入境检验检疫局 Piezoelectric biological chip for detecting disease cause of mad cattle disease and its preparation method
EP1394715A1 (en) * 2002-08-02 2004-03-03 Europroteome AG An expert system for clinicial outcome prediction
US7329739B2 (en) 2002-08-20 2008-02-12 Summit Glycoresearch Corporation Use of lectin library for distinguishing glycoproteins or cells, diagnosing serum or cells, or fractionating glycoproteins or cells
DK1552303T3 (en) 2002-10-16 2009-05-25 Univ Duke Biosensor for detecting glucose
DE10249608A1 (en) * 2002-10-18 2004-05-06 Gkss-Forschungszentrum Geesthacht Gmbh Device and method for structural analysis and detection of complex glycostructures
US20050186645A1 (en) 2003-12-18 2005-08-25 Yehudit Amor Method for analyzing a glycomolecule
WO2005107491A2 (en) * 2004-05-05 2005-11-17 Northeastern University Multi-lectin affinity chromatography and uses thereof
US7279131B2 (en) * 2004-07-01 2007-10-09 Uop Llc Method and apparatus for mass analysis of samples
BRPI0611534A2 (en) 2005-05-12 2010-09-21 Novartis Ag Brachyspira hyodysenteriae genes and proteins and use for diagnosis and therapy.
US7470544B2 (en) * 2005-05-26 2008-12-30 Hewlett-Packard Development Company, L.P. Sensor array using sail
AU2006259153B2 (en) * 2005-06-14 2012-04-12 Cellzome Gmbh Process for the identification of novel enzyme interacting compounds
KR100673835B1 (en) 2005-08-16 2007-01-24 성균관대학교산학협력단 Method for assaying protein using surface plasmon resonance
EP3147365B1 (en) 2006-04-21 2019-12-04 Intervet International B.V. Pestivirus species
KR100775334B1 (en) * 2006-11-08 2007-11-09 성균관대학교산학협력단 Method of real time detection of pathogenic microorganism using the competitive immunoreaction-mediated flow type surface plasmon resonance biosensor
EP2149049A4 (en) * 2007-05-18 2010-07-07 Fujirebio Kk Chemical surface nanopatterns to increase activity of surface-immobilized biomolecules
CN101855553B (en) 2007-06-29 2014-06-11 韩国安国药品株式会社 Predictive markers for ovarian cancer
EP2363407A1 (en) 2008-02-28 2011-09-07 Murdoch University Novel sequences of Brachyspira, immunogenic compositions, methods for preparation and use thereof
WO2009117773A1 (en) 2008-03-27 2009-10-01 Murdoch University Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof
US8133356B2 (en) * 2008-06-19 2012-03-13 Nalco Company Method of monitoring microbiological deposits
US8569025B2 (en) 2009-06-29 2013-10-29 The University Of British Columbia Terpene synthases from santalum
JP5231495B2 (en) 2010-03-10 2013-07-10 日本電波工業株式会社 Microorganism detection method and microorganism detection apparatus
WO2012028697A1 (en) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Affinity purification system based on donor strand complementation
WO2012064286A1 (en) 2010-11-11 2012-05-18 Agency For Science, Technology And Research Targeting metabolic enzymes in human cancer
EP2759602A1 (en) 2013-01-25 2014-07-30 Charité - Universitätsmedizin Berlin Non-invasive prenatal genetic diagnostic methods
AU2014364898B2 (en) * 2013-12-19 2018-07-26 Illumina, Inc. Substrates comprising nano-patterning surfaces and methods of preparing thereof
US10073120B1 (en) 2014-08-18 2018-09-11 Board Of Regents For The University Of Nebraska Integrated vacuum-ultraviolet, mid and near-ultraviolet, visible, near, mid and far infrared and terahertz optical hall effect (OHE) instrument, and method of use
US9851294B1 (en) * 2014-08-18 2017-12-26 J.A. Woollam Co., Inc. Integrated mid-infrared, far infrared and terahertz optical Hall effect (OHE) instrument, and method of use
EP3026422B1 (en) 2014-11-26 2018-02-14 Universität Stuttgart An apparatus and a method for spectroscopic ellipsometry, in particular infrared spectroscopic ellipsometry
CN108254575B (en) * 2018-01-16 2019-12-10 中国科学院力学研究所 double-antibody sandwich detection method suitable for ellipsometric imaging sensor
WO2021186532A1 (en) * 2020-03-17 2021-09-23 日本電気株式会社 Noise removal device, noise removal method, and recording medium

Citations (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071409A (en) * 1976-05-20 1978-01-31 Corning Glass Works Immobilization of proteins on inorganic support materials
US4289747A (en) * 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4298689A (en) * 1978-09-25 1981-11-03 Research Corporation Gonorrhea diagnostic test
US4389392A (en) * 1979-01-30 1983-06-21 Otsuka Pharmaceutical Co., Ltd. Determination of tumor associated glycolinkage and diagnosis of cancers
US4562157A (en) * 1983-05-25 1985-12-31 National Research Development Corporation Diagnostic device incorporating a biochemical ligand
US4690715A (en) * 1982-06-18 1987-09-01 American Telephone And Telegraph Company, At&T Bell Laboratories Modification of the properties of metals
US4844613A (en) * 1986-11-03 1989-07-04 Stc Plc Optical surface plasmon sensor device
US4908112A (en) * 1988-06-16 1990-03-13 E. I. Du Pont De Nemours & Co. Silicon semiconductor wafer for analyzing micronic biological samples
US4973493A (en) * 1982-09-29 1990-11-27 Bio-Metric Systems, Inc. Method of improving the biocompatibility of solid surfaces
US4987032A (en) * 1987-06-26 1991-01-22 Fuji Photo Film Co., Ltd. Functional organic thin film and method of manufacture thereof
US5079600A (en) * 1987-03-06 1992-01-07 Schnur Joel M High resolution patterning on solid substrates
US5096807A (en) * 1985-03-06 1992-03-17 Murex Corporation Imaging immunoassay detection system with background compensation and its use
US5154808A (en) * 1987-06-26 1992-10-13 Fuji Photo Film Co., Ltd. Functional organic thin film and process for producing the same
US5160597A (en) * 1989-04-21 1992-11-03 Eniricerche S.P.A. Sensor with antigen chemically bonded to a semiconductor device
US5164299A (en) * 1990-03-20 1992-11-17 E. I. Du Pont De Nemours And Company Use of a mixture of conjugated and unconjugated solid phase binding reagent to enhance the performance of assays
US5205917A (en) * 1991-05-07 1993-04-27 Glyko, Inc. Fluorophore assisted carbohydrate electrophoresis diagnosis
US5242828A (en) * 1988-11-10 1993-09-07 Pharmacia Biosensor Ab Sensing surfaces capable of selective biomolecular interactions, to be used in biosensor systems
US5252743A (en) * 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
US5294369A (en) * 1990-12-05 1994-03-15 Akzo N.V. Ligand gold bonding
US5342692A (en) * 1986-11-20 1994-08-30 Biocircuits Corporation Lipid-protein compositions and articles and methods for their preparation
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5405783A (en) * 1989-06-07 1995-04-11 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of an array of polymers
US5405766A (en) * 1992-03-26 1995-04-11 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Immobilization of biologically active protein on a support with a 7-18 carbon spacer and a bifunctional phospholipid
US5412087A (en) * 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5429708A (en) * 1993-12-22 1995-07-04 The Board Of Trustees Of The Leland Stanford Junior University Molecular layers covalently bonded to silicon surfaces
US5472881A (en) * 1992-11-12 1995-12-05 University Of Utah Research Foundation Thiol labeling of DNA for attachment to gold surfaces
US5512131A (en) * 1993-10-04 1996-04-30 President And Fellows Of Harvard College Formation of microstamped patterns on surfaces and derivative articles
US5512492A (en) * 1993-05-18 1996-04-30 University Of Utah Research Foundation Waveguide immunosensor with coating chemistry providing enhanced sensitivity
US5514501A (en) * 1994-06-07 1996-05-07 The United States Of America As Represented By The Secretary Of Commerce Process for UV-photopatterning of thiolate monolayers self-assembled on gold, silver and other substrates
US5520787A (en) * 1994-02-09 1996-05-28 Abbott Laboratories Diagnostic flow cell device
US5571410A (en) * 1994-10-19 1996-11-05 Hewlett Packard Company Fully integrated miniaturized planar liquid sample handling and analysis device
US5593838A (en) * 1994-11-10 1997-01-14 David Sarnoff Research Center, Inc. Partitioned microelectronic device array
US5603351A (en) * 1995-06-07 1997-02-18 David Sarnoff Research Center, Inc. Method and system for inhibiting cross-contamination in fluids of combinatorial chemistry device
US5605662A (en) * 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US5620850A (en) * 1994-09-26 1997-04-15 President And Fellows Of Harvard College Molecular recognition at surfaces derivatized with self-assembled monolayers
US5622826A (en) * 1994-12-22 1997-04-22 Houston Advanced Research Center Method for immobilization of molecules on platinum solid support surfaces
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5629213A (en) * 1995-03-03 1997-05-13 Kornguth; Steven E. Analytical biosensor
US5635358A (en) * 1992-05-01 1997-06-03 Trustees Of The University Of Pennsylvania Fluid handling methods for use in mesoscale analytical devices
US5653939A (en) * 1991-11-19 1997-08-05 Massachusetts Institute Of Technology Optical and electrical methods and apparatus for molecule detection
US5677196A (en) * 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5677195A (en) * 1991-11-22 1997-10-14 Affymax Technologies N.V. Combinatorial strategies for polymer synthesis
US5688642A (en) * 1994-12-01 1997-11-18 The United States Of America As Represented By The Secretary Of The Navy Selective attachment of nucleic acid molecules to patterned self-assembled surfaces
US5700642A (en) * 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5719060A (en) * 1993-05-28 1998-02-17 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
US5731152A (en) * 1996-05-13 1998-03-24 Motorola, Inc. Methods and systems for biological reagent placement
US5744305A (en) * 1989-06-07 1998-04-28 Affymetrix, Inc. Arrays of materials attached to a substrate
US5810985A (en) * 1992-09-14 1998-09-22 Purdue Research Foundation Electrophoretically mediated chemical analysis
US5821343A (en) * 1996-04-25 1998-10-13 Medtronic Inc Oxidative method for attachment of biomolecules to surfaces of medical devices
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5861242A (en) * 1993-06-25 1999-01-19 Affymetrix, Inc. Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same
US5866345A (en) * 1992-05-01 1999-02-02 The Trustees Of The University Of Pennsylvania Apparatus for the detection of an analyte utilizing mesoscale flow systems
US5928880A (en) * 1992-05-01 1999-07-27 Trustees Of The University Of Pennsylvania Mesoscale sample preparation device and systems for determination and processing of analytes
US5976466A (en) * 1989-08-21 1999-11-02 The Board Of Regents Of The University Of Washington Multiple-probe diagnostic sensor
US6066448A (en) * 1995-03-10 2000-05-23 Meso Sclae Technologies, Llc. Multi-array, multi-specific electrochemiluminescence testing
US6228575B1 (en) * 1996-02-08 2001-05-08 Affymetrix, Inc. Chip-based species identification and phenotypic characterization of microorganisms
US6309822B1 (en) * 1989-06-07 2001-10-30 Affymetrix, Inc. Method for comparing copy number of nucleic acid sequences
US6551784B2 (en) * 1989-06-07 2003-04-22 Affymetrix Inc Method of comparing nucleic acid sequences
US7662560B2 (en) * 1996-06-25 2010-02-16 Michael Mecklenburg Broad specificity affinity arrays: a qualitative approach to complex sample discrimination

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766856A (en) 1984-03-19 1998-06-16 The Picower Institute For Medical Research Diagnostic method for evaluating advanced glycosylation endproducts using MAC-2 receptor
GB2217447A (en) * 1988-04-21 1989-10-25 Atomic Energy Authority Uk Bonding to metal surfaces
JPH05501611A (en) * 1989-11-13 1993-03-25 アフィマックス テクノロジーズ ナームロゼ ベノートスハップ Spatially addressable immobilization of antiligands on surfaces
DE3939973A1 (en) 1989-12-02 1991-06-06 Basf Ag TWO-DIMENSIONAL CRYSTALLIZED MACROMOLECULAR LAYERS
DE4039677A1 (en) 1990-12-12 1992-06-17 Boehringer Mannheim Gmbh UNIVERSAL BINDING FILM
WO1992015709A1 (en) * 1991-02-28 1992-09-17 Abbott Laboratories Scanning probe microscopy immunoassay
WO1993021528A1 (en) 1992-04-22 1993-10-28 Ecole Polytechnique Federale De Lausanne (Epfl) Lipid membrane sensors
CA2108705A1 (en) 1992-11-06 1994-05-07 Richard Barner Biologically recognizing layers on new ti02 waveguide for biosensors
US5536642A (en) 1993-09-09 1996-07-16 Barbera-Guillem; Emilio Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases
CA2133772A1 (en) 1993-11-19 1995-05-20 Yuji Yamada Method for assaying glycoconjugate and reagent thereof
IL107880A (en) 1993-12-05 2000-08-31 Yeda Res & Dev Galectin-8 and galectin-8-like proteins and DNA molecules coding therefor
GB9406371D0 (en) 1994-03-30 1994-05-25 Axis Genetics Ltd Nematicidal proteins
WO1995028962A1 (en) 1994-04-22 1995-11-02 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Inhibition of myelin destruction by interfering with the interaction between mac-2 and myelin
AU2897595A (en) 1994-07-14 1996-02-16 Technobiochip Biosensor and method and instrument for deposition of alternating monomolecular layers
SE9403245D0 (en) 1994-09-26 1994-09-26 Pharmacia Biosensor Ab Improvements relating to bilayer lipid membranes
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
EP0812434B1 (en) 1995-03-01 2013-09-18 President and Fellows of Harvard College Microcontact printing on surfaces and derivative articles
WO1996038726A1 (en) 1995-05-30 1996-12-05 Ecole Polytechnique Federale De Lausanne (Epfl) Covalently immobilized phospholipid bilayers on solid surfaces
WO1996039937A1 (en) 1995-06-07 1996-12-19 The Regents Of The University Of California Microfabricated devices for diagnostic applications
US6518168B1 (en) 1995-08-18 2003-02-11 President And Fellows Of Harvard College Self-assembled monolayer directed patterning of surfaces
WO1997014028A2 (en) 1995-10-11 1997-04-17 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
JP4054379B2 (en) 1995-12-01 2008-02-27 イノジェネティックス・ナムローゼ・フェンノートシャップ Impedance type detection system and manufacturing method thereof

Patent Citations (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071409A (en) * 1976-05-20 1978-01-31 Corning Glass Works Immobilization of proteins on inorganic support materials
US4298689A (en) * 1978-09-25 1981-11-03 Research Corporation Gonorrhea diagnostic test
US4289747A (en) * 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4389392A (en) * 1979-01-30 1983-06-21 Otsuka Pharmaceutical Co., Ltd. Determination of tumor associated glycolinkage and diagnosis of cancers
US4690715A (en) * 1982-06-18 1987-09-01 American Telephone And Telegraph Company, At&T Bell Laboratories Modification of the properties of metals
US4973493A (en) * 1982-09-29 1990-11-27 Bio-Metric Systems, Inc. Method of improving the biocompatibility of solid surfaces
US4562157A (en) * 1983-05-25 1985-12-31 National Research Development Corporation Diagnostic device incorporating a biochemical ligand
US5096807A (en) * 1985-03-06 1992-03-17 Murex Corporation Imaging immunoassay detection system with background compensation and its use
US4844613A (en) * 1986-11-03 1989-07-04 Stc Plc Optical surface plasmon sensor device
US5342692A (en) * 1986-11-20 1994-08-30 Biocircuits Corporation Lipid-protein compositions and articles and methods for their preparation
US5079600A (en) * 1987-03-06 1992-01-07 Schnur Joel M High resolution patterning on solid substrates
US5154808A (en) * 1987-06-26 1992-10-13 Fuji Photo Film Co., Ltd. Functional organic thin film and process for producing the same
US4987032A (en) * 1987-06-26 1991-01-22 Fuji Photo Film Co., Ltd. Functional organic thin film and method of manufacture thereof
US4908112A (en) * 1988-06-16 1990-03-13 E. I. Du Pont De Nemours & Co. Silicon semiconductor wafer for analyzing micronic biological samples
US5242828A (en) * 1988-11-10 1993-09-07 Pharmacia Biosensor Ab Sensing surfaces capable of selective biomolecular interactions, to be used in biosensor systems
US5160597A (en) * 1989-04-21 1992-11-03 Eniricerche S.P.A. Sensor with antigen chemically bonded to a semiconductor device
US5405783A (en) * 1989-06-07 1995-04-11 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of an array of polymers
US5744305A (en) * 1989-06-07 1998-04-28 Affymetrix, Inc. Arrays of materials attached to a substrate
US6309822B1 (en) * 1989-06-07 2001-10-30 Affymetrix, Inc. Method for comparing copy number of nucleic acid sequences
US6551784B2 (en) * 1989-06-07 2003-04-22 Affymetrix Inc Method of comparing nucleic acid sequences
US5445934A (en) * 1989-06-07 1995-08-29 Affymax Technologies N.V. Array of oligonucleotides on a solid substrate
US5976466A (en) * 1989-08-21 1999-11-02 The Board Of Regents Of The University Of Washington Multiple-probe diagnostic sensor
US5252743A (en) * 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
US5164299A (en) * 1990-03-20 1992-11-17 E. I. Du Pont De Nemours And Company Use of a mixture of conjugated and unconjugated solid phase binding reagent to enhance the performance of assays
US5294369A (en) * 1990-12-05 1994-03-15 Akzo N.V. Ligand gold bonding
US5205917A (en) * 1991-05-07 1993-04-27 Glyko, Inc. Fluorophore assisted carbohydrate electrophoresis diagnosis
US5653939A (en) * 1991-11-19 1997-08-05 Massachusetts Institute Of Technology Optical and electrical methods and apparatus for molecule detection
US5677195A (en) * 1991-11-22 1997-10-14 Affymax Technologies N.V. Combinatorial strategies for polymer synthesis
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5405766A (en) * 1992-03-26 1995-04-11 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Immobilization of biologically active protein on a support with a 7-18 carbon spacer and a bifunctional phospholipid
US5412087A (en) * 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5928880A (en) * 1992-05-01 1999-07-27 Trustees Of The University Of Pennsylvania Mesoscale sample preparation device and systems for determination and processing of analytes
US5635358A (en) * 1992-05-01 1997-06-03 Trustees Of The University Of Pennsylvania Fluid handling methods for use in mesoscale analytical devices
US5866345A (en) * 1992-05-01 1999-02-02 The Trustees Of The University Of Pennsylvania Apparatus for the detection of an analyte utilizing mesoscale flow systems
US5810985A (en) * 1992-09-14 1998-09-22 Purdue Research Foundation Electrophoretically mediated chemical analysis
US5472881A (en) * 1992-11-12 1995-12-05 University Of Utah Research Foundation Thiol labeling of DNA for attachment to gold surfaces
US5677196A (en) * 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5512492A (en) * 1993-05-18 1996-04-30 University Of Utah Research Foundation Waveguide immunosensor with coating chemistry providing enhanced sensitivity
US5719060A (en) * 1993-05-28 1998-02-17 Baylor College Of Medicine Method and apparatus for desorption and ionization of analytes
US5861242A (en) * 1993-06-25 1999-01-19 Affymetrix, Inc. Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5512131A (en) * 1993-10-04 1996-04-30 President And Fellows Of Harvard College Formation of microstamped patterns on surfaces and derivative articles
US5605662A (en) * 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US5429708A (en) * 1993-12-22 1995-07-04 The Board Of Trustees Of The Leland Stanford Junior University Molecular layers covalently bonded to silicon surfaces
US5520787A (en) * 1994-02-09 1996-05-28 Abbott Laboratories Diagnostic flow cell device
US5514501A (en) * 1994-06-07 1996-05-07 The United States Of America As Represented By The Secretary Of Commerce Process for UV-photopatterning of thiolate monolayers self-assembled on gold, silver and other substrates
US5620850A (en) * 1994-09-26 1997-04-15 President And Fellows Of Harvard College Molecular recognition at surfaces derivatized with self-assembled monolayers
US5571410A (en) * 1994-10-19 1996-11-05 Hewlett Packard Company Fully integrated miniaturized planar liquid sample handling and analysis device
US5681484A (en) * 1994-11-10 1997-10-28 David Sarnoff Research Center, Inc. Etching to form cross-over, non-intersecting channel networks for use in partitioned microelectronic and fluidic device arrays for clinical diagnostics and chemical synthesis
US5593838A (en) * 1994-11-10 1997-01-14 David Sarnoff Research Center, Inc. Partitioned microelectronic device array
US5688642A (en) * 1994-12-01 1997-11-18 The United States Of America As Represented By The Secretary Of The Navy Selective attachment of nucleic acid molecules to patterned self-assembled surfaces
US5622826A (en) * 1994-12-22 1997-04-22 Houston Advanced Research Center Method for immobilization of molecules on platinum solid support surfaces
US5629213A (en) * 1995-03-03 1997-05-13 Kornguth; Steven E. Analytical biosensor
US6066448A (en) * 1995-03-10 2000-05-23 Meso Sclae Technologies, Llc. Multi-array, multi-specific electrochemiluminescence testing
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5700642A (en) * 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5603351A (en) * 1995-06-07 1997-02-18 David Sarnoff Research Center, Inc. Method and system for inhibiting cross-contamination in fluids of combinatorial chemistry device
US6228575B1 (en) * 1996-02-08 2001-05-08 Affymetrix, Inc. Chip-based species identification and phenotypic characterization of microorganisms
US5821343A (en) * 1996-04-25 1998-10-13 Medtronic Inc Oxidative method for attachment of biomolecules to surfaces of medical devices
US5731152A (en) * 1996-05-13 1998-03-24 Motorola, Inc. Methods and systems for biological reagent placement
US7662560B2 (en) * 1996-06-25 2010-02-16 Michael Mecklenburg Broad specificity affinity arrays: a qualitative approach to complex sample discrimination

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100151472A1 (en) * 2008-11-12 2010-06-17 Nodality, Inc. Detection Composition
US8309306B2 (en) * 2008-11-12 2012-11-13 Nodality, Inc. Detection composition
US20100143925A1 (en) * 2008-11-21 2010-06-10 Michael Adler Conjugate complexes for analyte detection
US8927210B2 (en) * 2008-11-21 2015-01-06 Chimera Biotec Gmbh Conjugate complexes for analyte detection

Also Published As

Publication number Publication date
WO1997049989A2 (en) 1997-12-31
DE69737818D1 (en) 2007-07-26
AU3436397A (en) 1998-01-14
EP1021713A2 (en) 2000-07-26
SE9602545L (en) 1997-12-26
US6872522B1 (en) 2005-03-29
DE69737818T2 (en) 2008-03-06
JP2000513436A (en) 2000-10-10
US7662560B2 (en) 2010-02-16
JP2006349690A (en) 2006-12-28
JP3865409B2 (en) 2007-01-10
CA2258941A1 (en) 1997-12-31
ES2289760T3 (en) 2008-02-01
ATE364839T1 (en) 2007-07-15
AU729960B2 (en) 2001-02-15
SE9602545D0 (en) 1996-06-25
EP1021713B1 (en) 2007-06-13
WO1997049989A3 (en) 1998-02-12
US20050164274A1 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
EP1021713B1 (en) Array of affinity probes suitable for the measurement of the change in mass or thickness at its surface
Haab et al. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions
CN1249436C (en) Patterned deposition of antibody binding proteins for optical diffraction-based biosensors
EP1036332B1 (en) Multiple assay method
JP5185335B2 (en) Biochips for archiving biological samples and clinical analysis
Rubina et al. Why 3‐D? Gel‐based microarrays in proteomics
US20030044799A1 (en) Analysis using a distributed sample
CA2406133A1 (en) Biosensor and related method
WO2001014425A1 (en) Multipurpose diagnostic systems using protein chips
KR20080114685A (en) Methods for characterizing molecular interactions
US20020168692A1 (en) Biosensor detector array
US20040002064A1 (en) Toxin detection and compound screening using biological membrane microarrays
CA2286414A1 (en) Non-separation heterogenous assay for biological substance
WO2001040796A2 (en) Glycoarrays on the surface of biochips
Uchiyama et al. Development of a lectin microarray based on an evanescent‐field fluorescence principle
US9863941B2 (en) Microchip and method for detecting molecules and molecular interactions
AU729960C (en) Broad specificity affinity arrays: a qualitative approach to Complex sample discrimination
EP1434995A2 (en) Calibrating microarrays
Haab et al. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions
Scheller et al. Present state and frontiers in biosensorics
Mecklenburg et al. Differentiation of human serum samples by surface plasmon resonance monitoring of the integral glycoprotein interaction with a lectin panel
WO2003025580A1 (en) Parallel miniaturized quantitative immunoassays
Malmqvist et al. Biomolecular interaction analysis
Fuentes et al. Label-free detection of NAPPA: Surface plasmon resonance
NAPPA In post-genome era having sequence the human genome, one of the most important pursuits is to understand the function of gene-expressed proteins. Despite the immense progress in molecular biology and genetic, only a small fraction of the proteome is understood at the biochemical level.

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION